Pasithea Therapeutics Corp.
Data quality: 83%
$0.74
▼
$0.03
(-3.39%)
Mkt Cap: 18.46 M
Price
$0.74
Mkt Cap
18.46 M
Day Range
$0.70 — $0.78
52-Week Range
$0.28 — $3.79
Volume
2,580,287
Open $0.73
50D / 200D Avg
$0.80
7.23% below
50D / 200D Avg
$0.81
8.78% below
Quick Summary
Key Takeaways
Negative free cash flow of -15.21 M
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
-149.19%
Below sector avg (-53.41%)
ROIC-119.72%
Net MarginN/A
Op. MarginN/A
Safety
Debt / Equity
N/A
Current Ratio4.02
Interest CoverageN/A
Valuation
PE (TTM)
-0.90
Above sector avg (-1.48)
P/B Ratio1.51
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (1364 peers)
Peer Comparison
vs Manufacturing sector median (1364 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -0.9 | -1.5 |
| P/B | 1.5 | 1.6 |
| ROE % | -149.2 | -53.4 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
ETFs Holding This Stock
1.08% weight
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -20.43 M |
| ROE | -149.19% | ROA | -133.34% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -15.21 M |
| ROIC | -119.72% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 4.02 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 4.15 M | Tangible Book Value | 4.11 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0.90 | Forward P/E | N/A |
| P/B Ratio | 1.51 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -82.41% | ||
| Market Cap | 18.46 M | Enterprise Value | 14.34 M |
| Per Share | |||
| EPS (Diluted TTM) | -2.91 | Revenue / Share | N/A |
| FCF / Share | -0.61 | OCF / Share | -0.61 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 74.47% |
| SBC-Adj. FCF | -15.57 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | 486,559.0 | 15,062.0 |
| Net Income | -20.43 M | -13.90 M | -15.96 M | -13.94 M | -2.17 M |
| EPS (Diluted) | -2.91 | -0.42 | -0.42 | -0.53 | — |
| Gross Profit | — | — | — | — | -2,213.0 |
| Operating Income | -20.86 M | -14.25 M | -15.98 M | -14.82 M | -4.51 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 7.98 M | 7.20 M | 8.10 M | 2.67 M | — |
| SG&A Expenses | — | 7.05 M | 7.88 M | 12.52 M | 4.51 M |
| D&A | — | — | — | — | — |
| Interest Expense | — | — | — | 102.0 | -508.0 |
| Income Tax | — | — | — | — | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 60.24 M | 16.06 M | 26.12 M | 45.18 M | 53.32 M |
| Total Liabilities | 5.02 M | 1.28 M | 2.72 M | 2.68 M | 1.90 M |
| Shareholders' Equity | 55.22 M | 14.78 M | 23.40 M | 42.50 M | 51.42 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 55.16 M | 6.92 M | 16.33 M | 33.15 M | 52.97 M |
| Current Assets | 56.46 M | 7.37 M | 16.69 M | 34.08 M | 53.30 M |
| Current Liabilities | 4.97 M | 1.12 M | 2.63 M | 1.88 M | 447,280.0 |
{"event":"ticker_viewed","properties":{"ticker":"KTTA","listing_kind":"stock","pathname":"/stocks/ktta","exchange":"Nasdaq","country":"US"}}